- Home
- RSVR vs ANNX Comparison
RSVR vs ANNX Comparison
Compare RSVR & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSVR
- ANNX
- Stock Information
- Founded
- RSVR 2007
- ANNX 2011
- Country
- RSVR United States
- ANNX United States
- Employees
- RSVR N/A
- ANNX N/A
- Industry
- RSVR Movies/Entertainment
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- RSVR Consumer Discretionary
- ANNX Health Care
- Exchange
- RSVR Nasdaq
- ANNX Nasdaq
- Market Cap
- RSVR 562.3M
- ANNX 668.8M
- IPO Year
- RSVR N/A
- ANNX 2020
- Fundamental
- Price
- RSVR $8.72
- ANNX $6.12
- Analyst Decision
- RSVR Strong Buy
- ANNX Strong Buy
- Analyst Count
- RSVR 1
- ANNX 7
- Target Price
- RSVR $12.50
- ANNX $15.80
- AVG Volume (30 Days)
- RSVR 33.5K
- ANNX 1.2M
- Earning Date
- RSVR 10-30-2024
- ANNX 11-14-2024
- Dividend Yield
- RSVR N/A
- ANNX N/A
- EPS Growth
- RSVR N/A
- ANNX N/A
- EPS
- RSVR N/A
- ANNX N/A
- Revenue
- RSVR $149,606,040.00
- ANNX N/A
- Revenue This Year
- RSVR $7.18
- ANNX N/A
- Revenue Next Year
- RSVR $7.33
- ANNX N/A
- P/E Ratio
- RSVR N/A
- ANNX N/A
- Revenue Growth
- RSVR 10.84
- ANNX N/A
- 52 Week Low
- RSVR $5.76
- ANNX $2.27
- 52 Week High
- RSVR $9.25
- ANNX $8.40
- Technical
- Relative Strength Index (RSI)
- RSVR 53.17
- ANNX 30.04
- Support Level
- RSVR $8.79
- ANNX $6.85
- Resistance Level
- RSVR $9.25
- ANNX $7.63
- Average True Range (ATR)
- RSVR 0.34
- ANNX 0.32
- MACD
- RSVR -0.02
- ANNX -0.17
- Stochastic Oscillator
- RSVR 50.93
- ANNX 6.22
About RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. The company's segment includes Music Publishing; Recorded Music and others. It generates the maximum of its revenue from the Music Publishing segment.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.